PRTN3 and inflammatory response: The recently reported results of ARIAA study were also in line with this, wherein targeting T cell co-stimulation with abatacept for 6 months significantly decreased subclinical joint inflammation and the incidence of new-onset arthritis in ACPA+ subjects with arthralgia and imaging evidence of joint inflammation (306).